Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3
Status:
Completed
Trial end date:
2020-07-14
Target enrollment:
Participant gender:
Summary
The purpose of this survey is to determine the incidence rate of cardiovascular (CV) events
associated with long-term treatment with and without omega-3 fatty acid ethyl esters (Lotriga
Granular Capsules) in high-risk hyperlipidemic patients treated by statin in daily medical
practice.